Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Patients with type 2 diabetes are at an increased risk for developing atherosclerosis,
largely due to the underlying insulin resistance and chronic low grade inflammation.
Cardiovascular events could be prevented with proper interventions targeted at ameliorating
the aforementioned detrimental processes. YKL-40, a novel surrogate marker of acute and
chronic inflammatory states has been implicated to have a putative role in both pathways.
Given the shared pathway of insulin resistance and atherosclerosis, it is conceivable that
anti-diabetes medications are able to modify coronary artery disease risk via direct and
indirect amelioration of YKL-40 concentrations. The present clinical trial was therefore
launched to examine the comparative effects of metformin and pioglitazone, two commonly
prescribed anti-diabetes medications on YKL-40 concentrations in medication-naïve,
newly-diagnosed type 2 diabetes patients.